Company

About

Biolojic Design

Biolojic Design

Revohot, Israel

Biolojic Design makes developable, active human antibodies directed against functional epitopes, including targets for which existing technologies fail.

Biomica

Biomica

Rehovot, HaMerkaz, Israel

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

Biond Biologics

Biond Biologics

Misgav Industrial Park, Israel

Biond Biologics is an Israeli clinical-stage biopharmaceutical company Biond is an innovative biotech company developing breakthrough immunotherapies and a pioneering intracellular drug delivery platform for the treatment of cancer patients. Our innovation: Biologics targeting novel immune evasion mechanisms, discovered through in-house research utilizing real-world patient and tumor samples A transformative intracellular delivery platform for biologics, e.g., antibodies or enzymes, inside cells, allowing to drug intracellular targets currently considered "undruggable". Biond Biologics – Novel and innovative immunotherapies for cancer and auto-immune diseases.

Nectin Therapeutics

Nectin Therapeutics

Jerusalem, Israel

Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system. We are developing a collection of next-generation immunotherapy agents. Despite the unprecedented efficacy of existing immunotherapy agents, many patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered novel resistance mechanisms and developed novel agents targeting these mechanisms for improved therapy. At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.